GlassScriptPhysician profile
Nibu Mathew
NPI 1538231261
$5,639.96
in general payments reported to CMS, 2019-2025
19 companies · $1,460 in 2025
The $1,460 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $242 · 2021: $783 · 2022: $966 · 2023: $633 · 2024: $1,288 · 2025: $1,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,380.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,536.09 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $713.70 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $635.60 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $502.59 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.40 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $398.99 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Abbott Laboratories | $259.28 | 2022-2023 | Freestyle Libre 3 |
| Abiomed | $186.94 | 2023 | Impella |
| Stryker Corporation | $157.59 | 2024 | Mako |
| Boston Scientific Corporation | $151.79 | 2021-2025 | Watchman Access System |
| Amarin Pharma, INC. | $129.38 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $121.86 | 2023 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $87.37 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $79.83 | 2019-2023 | Livalo |
| Glaxosmithkline, LLC. | $73.71 | 2022-2024 | Arexvy, Trelegy Ellipta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $68.55 | 2022-2025 | |
| Abbvie INC. | $67.15 | 2025 | |
| Merck Sharp & Dohme LLC | $22.75 | 2019-2021 | |
| Dexcom, INC. | $22.39 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nibu Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.